NewAmsterdam Pharma N.V. (NAMSW)
undefined
undefined%
At close: undefined
13.02
-3.41%
After-hours Dec 13, 2024, 03:03 PM EST

Income Statement (Annual)

Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year FY23 FY22 FY21 FY20
Revenue 12.76M 95.91M - -
Cost of Revenue - - - -
Gross Profit 12.76M 95.91M - -
Operating Income -165.73M -3.32M -30.73M -5.43M
Interest Income 10.22M 268.03K 361.10K 344.00K
Pretax Income -160.25M -21.14M -36.71M -5.75M
Net Income -176.94M -21.14M -36.71M -5.75M
Selling & General & Admin 29.77M 18.22M 5.27M 1.38M
Research & Development 159.42M 81.01M 25.46M 4.04M
Other Expenses - - - -
Operating Expenses 197.06M 116.78M 36.35M 5.40M
Interest Expense 6.80M - - -
Selling & Marketing Expenses 4.06M 1.60M 858.39K 11.00K
Cost & Expenses 183.23M 116.78M 36.35M 5.40M
Income Tax 27.00K - - -
Shares Outstanding (Basic) 82.16M 18.97M 17.75M 17.75M
Shares Outstanding (Diluted) 82.16M 18.97M 17.75M 17.75M
EPS (Basic) -2.15 -1.11 -3.34 -1.15
EPS (Diluted) -2.15 -1.11 -3.34 -1.15
EBITDA -176.86M -3.31M -30.73M -5.43M
Depreciation & Amortization 49.00K 8.40K 4.39K 1K